Abstract
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Survival probability of pediatric ALL had been dismal at 50 years ago, but the most recent clinical trials with multiagent chemotherapy have achieved overall survival probability of better than 80%, thanks to better supportive care, treatment stratification based on relapse risk, and the biological features of leukemic cells. Diagnosis of ALL was based principally on morphological identification of leukemic blasts in bone marrow, and immunophenotype assessment by flow cytometry is necessary, and most pediatric ALL cases are clinically classified as B-cell precursor, T-cell ALL, or mature B-cell types, comprising 80%, 15%, and 5% of cases, respectively.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Horibe K, Saito AM, Takimoto T, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98:74–88.
Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–55.
Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–48.
Kato M, Koh K, Kikuchi A, et al. Case series of pediatric acute leukemia without a peripheral blood abnormality, detected by magnetic resonance imaging. Int J Hematol. 2011;93:787–90.
Kobayashi R, Sunami S, Mitsui T, et al. Treatment of pediatric lymphoma in Japan: current status and plans for the future. Pediatr Int. 2015;57:523–34.
Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17:e231–9.
Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295–305.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kato, M. (2020). Overview. In: Kato, M. (eds) Pediatric Acute Lymphoblastic Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-15-0548-5_1
Download citation
DOI: https://doi.org/10.1007/978-981-15-0548-5_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-0547-8
Online ISBN: 978-981-15-0548-5
eBook Packages: MedicineMedicine (R0)